177 Lu-FAP-2286 Therapy for Advanced Lung Adenocarcinoma With Multiple Metastases : A Promising Last-line Treatment Option.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 41432572.
- Also identified by DOI 10.1097/RLU.0000000000006271 and PMC identifier 13132036.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 62-year-old man was diagnosed with lung adenocarcinoma and metastases involving the bone, muscle, peritoneum, and lymph nodes. He received one cycle of 177 Lu-FAP-2286 therapy. One month after treatment, the clinical symptoms, including chest pain, shortness of breath, and productive cough, had completely resolved. Follow-up 68 Ga-FAP-2286 imaging at 2 months demonstrated partial metabolic response (PERCIST 1.0), accompanied by a marked reduction in respiratory tumor marker levels. In addition, no adverse reactions were reported by the patient.
Medical subject headings
- Lung Neoplasms
- Adenocarcinoma
- Lutetium
- Radioisotopes